ACE and congestive heart failure: Some studies compared pimobendan and ACE inhibitors, such as the QUEST study [250], and the results showed that pimobendan, in combination with the standard therapy (diuretics and digoxin), administered at a dosage of 0.4–0.6 mg/kg/day prolonged the expectancy and quality of life in patients affected by CHF secondary to MMVD [251].